(E)-N'-(2-hydroxy-3-methoxybenzylidene)benzohydrazide

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: (E)-N'-(2-hydroxy-3-methoxybenzylidene)benzohydrazide
• 英文别名: (2-hydroxy-3-methoxybenzylidene)benzohydrazide；N'-(2-hydroxy-3-methoxybenzylidene)benzohydrazide；N-[(E)-(2-hydroxy-3-methoxyphenyl)methylideneamino]benzamide
• 化学式: C₁₅H₁₄N₂O₃
• 分子量: 270.288
• InChiKey: NOQSDVQYJGUDMC-MHWRWJLKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  70.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-N'-(2-hydroxy-3-methoxybenzylidene)benzohydrazide 、 甲醇 、 bis(acetylacetonate)oxovanadium 在 air 作用下， 以 甲醇 为溶剂， 以71%的产率得到[V(V)O((E)-N'-(2-hydroxy-3-methoxybenzylidene)benzohydrazide-2H)(OCH3)(OHCH3)]*methanol
  参考文献：
  名称：

  Vanadiumoxo–aroylhydrazone complexes: Synthesis, structure and DFT calculations

  摘要：

  The aroylhydrazone Schiff base ligands (E)-N'-(2-hydroxybenzylidene)benzohydrazide = H(2)L(1), (E)-N'-(2-hydroxy-3-methoxybenzylidene)benzohydrazide = H(2)L(2) and = (E)-N'-(5-bromo-2-hydroxybenzylidene)benzohydrazide = H(2)L(3) gave the vanadium(V)oxo-aroylhydrazone complexes [V(V)OL(1)(OCH(3))(OHCH(3)] (1), [V(V)OL(2)(OCH(3))(OHCH(3)]center dot CH(3)OH (2) and [V(V)OL(3)(OCH(3))(OHCH(3)] (3) on reaction with vanadium(IV) oxide acetylacetonate. The complexes were characterized by spectroscopic methods in the solid state (IR) and in solution (UV-Vis, (1)H NMR). Single crystal X-ray analysis was performed with 3. In methanol solution six-coordinated V(V)OL(3)(OCH(3))(OHCH(3)) was formed. V(IV) was oxidized to V(V) by aerial oxygen in the synthesis. In the VO(5)N coordination sphere the alcohol oxygen lies trans to the oxo oxygen. The general V-O bond length order is oxo < methoxylato < phenoxidic < enolato < alcoholic. The complexes are mononuclear, but intermolecular O-H center dot center dot center dot-N hydrogen bonding affords a zigzag chain. OFT calculations on complex 3 reproduced the geometric parameters. IR and UV-Vis spectroscopic data well in a reasonable range. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2010.09.029
• 作为产物：
  描述：

  苯甲酰肼 、 邻香草醛 以 N,N-二甲基甲酰胺 为溶剂， 生成 (E)-N'-(2-hydroxy-3-methoxybenzylidene)benzohydrazide
  参考文献：
  名称：

  Design, synthesis and in vitro antimalarial activity of an acylhydrazone library

  摘要：

  A library of acylhydrazone iron chelators was synthesized and tested for its ability to inhibit the growth of a chloroquine-resistant strain of Plasmodium falciparum. Some of these new compounds are significantly more active than desferrioxamine DFO, the iron chelator in widespread clinical use and also than the most effective chelators. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.09.058

文献信息

• Theramutein modulators
  申请人：Housey Gerad M.

  公开号：US20100016298A1

  公开（公告）日：2010-01-21

  This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

  这项发明涉及的是抑制或激活内源性蛋白变异形式的试剂以及识别这些变异的新方法。特别感兴趣的是那些由突变基因编码的内源性蛋白变异的抑制剂和激活剂，这些变异通常是在暴露于已知是相应未突变内源性蛋白的抑制剂或激活剂的化学试剂之后出现，或者至少是首次被识别为由此类化学试剂引起的。
• Aza-Michael Addition Reactions of Hydrazones with Activated Alkynes Catalyzed by Nitrogen-Containing Organic Bases
  作者：Zhi-Liang Yuan、Yin Wei、Min Shi

  DOI：10.1002/ejoc.201000365

  日期：2010.7

  2]-octane)-catalyzed Michael-type reactions of hydrazones with activated alkynes are described in this paper. This aza-Michael addition reaction can be applied to different types of hydrazones, such as hydrazones 1 and hydroxy-bearing hydrazones 5. The corresponding adducts are achieved in high yields under mild reaction conditions. DABCO-promoted aza-Michael addition reactions were successfully applied to

  本文描述了几种高效的 DABCO（1,4-二氮杂双环 [2.2.2]-辛烷）催化腙与活化炔烃的迈克尔型反应。这种氮杂-迈克尔加成反应可以应用于不同类型的腙，如腙1和含羟基的腙5。相应的加合物在温和的反应条件下以高产率获得。DABCO 促进的氮杂-迈克尔加成反应成功地应用于一系列具有活化炔烃的腙，以中等至良好的产率提供相应的加合物。
• SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER
  申请人：Young David H.

  公开号：US20120010075A1

  公开（公告）日：2012-01-12

  The present invention relates to the use of mixtures containing hydrazone compounds and copper for controlling the growth of fungi.

  本发明涉及使用含有肼化合物和铜的混合物来控制真菌生长。
• Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
  申请人：HMI Medical Innovations, LLC

  公开号：US10018619B2

  公开（公告）日：2018-07-10

  This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost reductions in the drug discovery process resulting from the corresponding increases in efficiency.

  本发明涉及鉴定、合成、优化和剖析作为蛋白质抑制剂或激活剂的化合物的方法，这些蛋白质既包括天然存在的内源性蛋白质，也包括内源性蛋白质的某些变体形式，以及鉴定这些变体的新方法。该方法通过改进新药鉴定、先导物优化、生物分析和快速消除有毒化合物，简化了药物发现和创造过程，从而加快了作为潜在治疗药物的化合物的鉴定和开发。该方法的实施可相应提高效率，从而降低药物发现过程的总体成本。
• Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
  申请人：HMI Medical Innovations, LLC

  公开号：US10473643B2

  公开（公告）日：2019-11-12

  This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost reductions in the drug discovery process resulting from the corresponding increases in efficiency.

  本发明涉及鉴定、合成、优化和剖析作为蛋白质抑制剂或激活剂的化合物的方法，这些蛋白质既包括天然存在的内源性蛋白质，也包括内源性蛋白质的某些变体形式，以及鉴定这些变体的新方法。该方法通过改进新药鉴定、先导物优化、生物分析和快速消除有毒化合物，简化了药物发现和创造过程，从而加快了作为潜在治疗药物的化合物的鉴定和开发。该方法的实施可相应提高效率，从而降低药物发现过程的总体成本。